Dermavant Sciences names Fouse executive chairman

Dermavant Sciences has announced the appointment of Jacqualyn "Jackie" Fouse, PhD, as its executive chairman.

Fouse had previously served as president and chief operating officer of Celgene Corporation until April 2017, and was on Celgene's board of directors through June 2017. She also had served as chief financial officer and president of the company’s global hematology and oncology franchise at Celgene, and her experienced included working with the business unit that launched Otezla (apremilast) for treating moderate-to-severe plaque psoriasis and psoriatic arthritis, according to a news release from Dermavant.

Dermavant, a biopharmaceutical company that develops and commercializes therapies in medical dermatology, reports it is developing three investigational drugs, RVT-501, RVT-502, and RVT-201.

RVT-501 is a selective topical phosphodiesterase-4 inhibitor in phase 2 development for patients with mild-to-moderate atopic dermatitis.

RVT-502, also known as cerdulatinib, is a dual spleen tyrosine kinase and Janus kinase inhibitor topical therapy for a variety of serious dermatologic conditions.

RVT-201, a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines, is being developed for inflammatory skin diseases, according to Dermavant.

Reference: www.dermavantsciences.com